Lykiri et al., sorry to say this that we shouldn't attempt to quantify mPFS or mOS in immunotherapy trials is my argument. These parameters only help the short addicts mafias. We should only talk about the OS tails. Or write the abstracts in terms percentage of patients alive year 1, 2, 3, 4, and 5 so on so forth. And compare with if there are any data out there in the world or whatever out there in the ECAs.
Thank you Lykiri for reminding me of the 7.6 months placebo group mPFS. I totally forgot that graph. Just wondering how much higher than 7.6 months was the mPFS of the 64 crossovers and how much lower was the mPFS of the 29 remaining permanent placebos.
Market Data 
Markets 
AI
